What Comac Medical does

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Sofia, Bulgaria, delivering clinical trial services from Phase I through Phase IV, including post-marketing, medical device, nutraceutical, biosimilar, and generics studies. The company was founded in 1998 and operates across 24+ countries with 350+ employees, leveraging a fully owned, Europe-based Early Phase Clinical Research Unit and an in-house GCLP-accredited Bioanalytical Laboratory. Its customer base spans major pharmaceutical companies, biotechnology firms, and other CROs, and it is recognized as a Top 10 CRO in Europe.

The company's service portfolio is organized into integrated solutions and services covering early phase trials, late phase trials, post-marketing studies, medical devices and nutraceuticals, and biosimilars/generics, supported by a Functional Service Provider (FSP) offering for flexible resourcing. Comac monetizes through quote-based, project-priced professional services engagements on multi-year contracts, sold through a direct enterprise sales motion supplemented by heavy participation in industry conferences (OCT Europe, Swiss Biotech Day, BioEurope, ASCO, ESMO). Comac holds ISO 9001:2015 certification, GCLP laboratory accreditation, French Ministry R&D approval, and has received FDA No Action Indicated (NAI) inspection letters.

In June 2023, Edgecap acquired a majority stake while founder Milen Vrabevski and management retained a meaningful minority. The company has since professionalized its executive team, appointing a new Group CEO, CFO, COO, and CCO, and in June 2025 acquired ILIFE Consulting, a Paris-based specialty CRO focused on oncology, rare diseases, and complex biotech trials. The combined platform is positioned as a flexible, cost-efficient boutique alternative to large global CROs, with deep Central and Eastern European reach and growing Western European and US presence.

Name

Comac Medical

Legal name

Comac Medical Ltd.

Website

https://comac-medical.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) headquartered in Bulgaria, delivering Phase I-IV clinical trials, bioanalytical, and FSP services to pharmaceutical, biotech, and CRO clients across 24+ countries.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical trial services
• Contract research organization
• Early phase trials
• Functional service provider
• Biopharma clinical research

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. CRO Services - Clinical Trial Management: Full-service Contract Research Organization services managing clinical trials from Phase I through Phase IV, including project management, monitoring, data management, and regulatory affairs
2. Early Phase Clinical Research Unit: Dedicated early phase clinical trial unit providing first-in-human and proof-of-concept studies for pharmaceutical and biotech sponsors
3. Functional Service Provider (FSP): Flexible staffing and functional service solutions providing dedicated resources or functional support to sponsors
4. Medical Devices & Nutraceuticals: Clinical investigation services for medical devices and food supplements/nutraceuticals
5. Biosimilar & Generics Development: Clinical development services specifically designed for biosimilar and generic pharmaceutical products

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Comac Medical is a full-service Pan-European Contract Research Organization (CRO) delivering clinical trial solutions from Phase I through Phase IV. Its offering spans early-phase clinical trials, late-phase trials, post-marketing trials, medical device and nutraceutical investigations, and biosimilar/generics development, supported by a Europe-based fully owned Early Phase Clinical Research Unit and in-house Bioanalytical Lab. It also provides Functional Service Provider (FSP) and dedicated resource/consulting services to pharmaceutical, biotech, and other CRO clients across 24+ countries.

Product overview

Comac Medical is a pan-European, full-service Contract Research Organization (CRO) offering an integrated portfolio of clinical trial solutions spanning early phase (Phase I-II), late phase (Phase III-IV), post-marketing trials, medical devices, and biosimilar/generics services. The core offering is organized around Solutions (Early Phase Clinical Trials, Late Phase Clinical Trials, Post Marketing Trials, Medical Devices & Nutraceuticals, Biosimilar & Generics) and Services (CRO Services, Early Phase Clinical Research Unit, and Functional Service Provider). The company also maintains a fully owned Europe-based Early Phase Unit and Bioanalytical Lab, supporting end-to-end trial delivery from a single platform.

Differentiator

Problem solved

Functional benefit

Brands

• ILIFE Consulting: Specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché.

Products and services

• Early Phase Clinical Trials Comprehensive Phase I-II early phase clinical trial solutions leveraging a Europe-based fully owned Early Phase Unit and Bioanalytical Lab, tailored for biotech and complex clinical studies including oncology and rare diseases.
• Late Phase Clinical Trials Full-service Phase III-IV late phase clinical trial management and execution across diverse European regions.
• Post Marketing Trials Post-marketing surveillance and observational trial services supporting product lifecycle management.
• Medical Devices & Nutraceuticals Clinical investigation services for medical devices and food supplements, covering regulatory and execution needs.
• Biosimilar & Generics Specialized clinical trial services for biosimilar and generic pharmaceutical products.
• Contract Research Organization (CRO) Services Full-service CRO services covering study design, project management, site monitoring, data management, and regulatory affairs across all trial phases.
• Early Phase Clinical Research Unit Europe-based, fully owned early phase clinical research unit and bioanalytical laboratory, combining long-term expertise with cutting-edge facilities in one location; operates 2 Early Phase Unit locations.
• Functional Service Provider (FSP) Flexible FSP model providing targeted functional services including clinical monitoring, data management, pharmacovigilance, and regulatory support.

Quantifiable outcome

• Industry-leading speed in patient recruitment, site access, and retention
• +3 more outcomes

Named customers20 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• ILIFE ConsultingcoreStrategic or Co-development Partner · 3 June 2025Comac Medical Group acquired ILIFE Consulting on June 3, 2025. ILIFE is a specialized CRO headquartered in Paris, France, renowned for expertise in oncology, rare diseases, and complex biotech clinical trials. Founded in 2013 by Marina Iché, ILIFE has built a distinguished reputation for delivering high-value strategic consulting alongside clinical trial execution. The acquisition strengthens Comac Medical's pan-European CRO network with deep expertise in early-phase biotech and oncology research. McDermott Will & Emery advised ILIFE Consulting on the acquisition.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Parexel International: Large global CRO (PE-owned by EQT/Goldman Sachs) covering all phases of clinical development with strong oncology and rare disease franchises. Direct competitor and listed Comac partner/customer.
• Syneos Health: Biopharma solutions organization offering full-service clinical development and commercial services. Direct competitor for Phase I-IV work and listed as a Comac customer for regional project execution in Europe.
• IQVIA: Largest global CRO with comprehensive clinical, data and technology offerings. Direct competitor for enterprise pharma contracts and listed as both customer and competitor in Comac's ecosystem, illustrating the prime/subcontractor dynamic.
• Worldwide Clinical Trials: Mid-size global CRO with strong specialty therapeutic focus including oncology, rare disease and CNS. Highly comparable to Comac's post-ILIFE positioning as a flexible, science-led alternative to mega-CROs.
• ICON plc: Global full-service CRO offering Phase I-IV clinical trial management, FSP, biometrics and laboratory services across all major geographies. Direct competitor to Comac for Big Pharma and biotech trial awards, and simultaneously a Comac customer/partnership counterparty.
• Medpace Holdings: Mid-to-large full-service CRO focused on small and mid-sized biopharma, with deep therapeutic-area expertise. Closest comparable in size and operating model to Comac, particularly following the ILIFE acquisition that mirrors Medpace's biotech specialization.

Emerging players

• Clinipace Worldwide: Mid-size CRO with European presence and therapeutic-area focus across oncology and rare diseases. Comparable emerging player competing for similar biotech and mid-pharma sponsors.
• Clario: Specialized provider of clinical endpoint and data management technology and services for clinical trials. Adjacent competitor in biometrics, eCOA and central lab services where Comac also offers capabilities.

Broad incumbents

• PPD (Thermo Fisher Scientific): Thermo Fisher-owned global CRO providing comprehensive clinical development and laboratory services. Operates broadly across all therapeutic areas and geographies; listed as a Comac customer for regional execution.
• Charles River Laboratories: Major preclinical and clinical CRO with deep laboratory and early-phase capabilities. Overlaps with Comac's Early Phase Unit and Bioanalytical Lab offering, though primarily positioned upstream in preclinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/comac-medical

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comac Medical